Indication
Somatostatin Receptor Positive
3 clinical trials
3 products
1 drug
Clinical trial
Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand TherapyStatus: Not yet recruiting, Estimated PCD: 2029-07-01
Drug
68Ga-DOTATATEProduct
[203Pb]VMT-alpha-NETProduct
[212Pb]VMT-alpha-NETClinical trial
A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).Status: Not yet recruiting, Estimated PCD: 2028-06-01
Product
Lutetium Lu 177-EdotreotideClinical trial
Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersStatus: Not yet recruiting, Estimated PCD: 2029-01-01